• FLASCO
• March 10, 2015
• Drugs

Lenvima (lenvatinib)

The U.S. Food and Drug Administration granted approval to Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease). Please see full Prescribing Information.